Back to Search
GREGORY WISEMAN, M.D.
M.D.
Internal Medicine Physician
NPI: 1912973736Individual
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
01025482(IN)
Research & Publications (20)
Weight-based dosing of Yttrium 90 ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
PMID 18021468·Clin Lymphoma Myeloma·2007
3-trial
Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
PMID 15869453·Cancer Biother Radiopharm·2005
8-other
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy.
PMID 12804052·Cancer Biother Radiopharm·2003
3-trial
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
PMID 12804042·Cancer Biother Radiopharm·2003
3-trial
Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
PMID 12621016·J Nucl Med·2003
3-trial
Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma.
PMID 11877765·Cancer·2002
3-trial
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
PMID 12036859·Blood·2002
3-trial
Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma.
PMID 10952488·Eur J Nucl Med·2000
3-trial
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.
PMID 19255322·J Clin Oncol·2009
3-trial
Measuring granulocyte and monocyte accumulation at malignant lymphoma sites.
PMID 19029411·J Clin Oncol·2009
8-other
The value of [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography in extranodal natural killer/T-cell lymphoma.
PMID 18501102·Clin Lymphoma Myeloma·2008
8-other
18F-FDG PET in the management of patients with anaplastic thyroid carcinoma.
PMID 18630999·Thyroid·2008
8-other
Positron emission tomography using F-18 fluorodeoxyglucose pre- and post-autologous stem cell transplant in non-Hodgkin's lymphoma.
PMID 18391991·Bone Marrow Transplant·2008
6-review
The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
PMID 17414887·Nucl Med Commun·2007
8-other
Clinical significance of diffusely increased 18F-FDG uptake in the thyroid gland.
PMID 17504869·J Nucl Med·2007
8-other
A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma.
PMID 17705349·Cancer Immun·2007
3-trial
A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
PMID 17875803·Clin Cancer Res·2007
3-trial
18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients.
PMID 17901765·Nucl Med Commun·2007
8-other
Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma.
PMID 17979571·Cancer Biother Radiopharm·2007
1-meta
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 712 N LINCOLN ST
GREENSBURG, IN 47240 - Phone
- (812) 663-8079
Quick Facts
- NPI
- 1912973736
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile